The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?

In-House Versus Outsource: A Decision-Making Guide

Whitepaper

The biologics market is quickly evolving from a focus on developing blockbuster drugs to exploring niche markets with unmet needs. While the changes are exciting, they pose several risks to a molecule’s success as competition intensifies, timelines shorten and capacity challenges emerge. Yesterday’s solutions may not be a perfect fit for today’s molecules.

Authors:
Barry Rosenblatt, PhD President, SME Biotech Consulting
Dave Kenyon, PhD Vice President, Process Sciences Pharma Services Patheon, by Thermo Fisher Scientific